Misplaced Pages

Bromodeoxyuridine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 23:06, 21 May 2024 editCitation bot (talk | contribs)Bots5,429,053 edits Added bibcode. | Use this bot. Report bugs. | Suggested by Abductive | | #UCB_Category 5/85← Previous edit Latest revision as of 18:51, 15 June 2024 edit undoAngelHerraez (talk | contribs)132 edits ammending date of publication 
Line 50: Line 50:
During the ] of the ] (when ] occurs), BrdU can be incorporated in place of thymidine in newly synthesized ] molecules of dividing cells.<ref name="Ki-67 V. BrdU">{{cite journal|last=Kee| first=N |author2=S Sivalingam |author3=R Boonstra |author4=J.M Wojtowicz|title=The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis|journal=Journal of Neuroscience Methods|date=March 2002|volume=115|issue=1| pages=97–105|doi=10.1016/S0165-0270(02)00007-9|pmid=11897369|hdl=1807/357 |s2cid=17572667 |hdl-access=free}}</ref> Cells that have recently performed DNA replication or ] can be detected with ] specific for BrdU using techniques such as ] or ].<ref name=pmid21785232>{{cite journal |pages=433–40 |doi=10.1269/jrr.10097 |title=Visualization of Heavy Ion Tracks by Labeling 3'-OH Termini of Induced DNA Strand Breaks |year=2011 |last1=Konishi |first1=Teruaki |last2=Takeyasu |first2=Akihiro |last3=Natsume |first3=Toshiyuki |last4=Furusawa |first4=Yoshiya |last5=Hieda |first5=Kotaro |journal=Journal of Radiation Research |volume=52 |issue=4 |pmid=21785232|bibcode=2011JRadR..52..433K |doi-access= }}</ref> BrdU-labelled cells in humans can be detected up to two years after BrdU infusion.<ref name="Nature Neurogenesis">{{cite journal|last=Eriksson|first= Peter |author2=Ekaterina Perfilieva |author3=Thomas Björk-Eriksson |author4=Ann-Marie Alborn |author5=Claes Nordborg |author6=Daniel A. Peterson |author7=Fred H. Gage|title=Neurogenesis in the adult human hippocampus|journal=Nature Medicine|year=1998|volume=4|series=1313-1317|pages=1313–1317|doi=10.1038/3305|pmid=9809557|issue=11|doi-access=free}}</ref> During the ] of the ] (when ] occurs), BrdU can be incorporated in place of thymidine in newly synthesized ] molecules of dividing cells.<ref name="Ki-67 V. BrdU">{{cite journal|last=Kee| first=N |author2=S Sivalingam |author3=R Boonstra |author4=J.M Wojtowicz|title=The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis|journal=Journal of Neuroscience Methods|date=March 2002|volume=115|issue=1| pages=97–105|doi=10.1016/S0165-0270(02)00007-9|pmid=11897369|hdl=1807/357 |s2cid=17572667 |hdl-access=free}}</ref> Cells that have recently performed DNA replication or ] can be detected with ] specific for BrdU using techniques such as ] or ].<ref name=pmid21785232>{{cite journal |pages=433–40 |doi=10.1269/jrr.10097 |title=Visualization of Heavy Ion Tracks by Labeling 3'-OH Termini of Induced DNA Strand Breaks |year=2011 |last1=Konishi |first1=Teruaki |last2=Takeyasu |first2=Akihiro |last3=Natsume |first3=Toshiyuki |last4=Furusawa |first4=Yoshiya |last5=Hieda |first5=Kotaro |journal=Journal of Radiation Research |volume=52 |issue=4 |pmid=21785232|bibcode=2011JRadR..52..433K |doi-access= }}</ref> BrdU-labelled cells in humans can be detected up to two years after BrdU infusion.<ref name="Nature Neurogenesis">{{cite journal|last=Eriksson|first= Peter |author2=Ekaterina Perfilieva |author3=Thomas Björk-Eriksson |author4=Ann-Marie Alborn |author5=Claes Nordborg |author6=Daniel A. Peterson |author7=Fred H. Gage|title=Neurogenesis in the adult human hippocampus|journal=Nature Medicine|year=1998|volume=4|series=1313-1317|pages=1313–1317|doi=10.1038/3305|pmid=9809557|issue=11|doi-access=free}}</ref>


Because BrdU can replace ] during DNA replication, it can cause ]s, and its use is therefore potentially a health hazard.{{cn|date=March 2021}} However, because it is neither ] nor ] at labeling concentrations, it is widely preferred for ''in vivo'' studies of ] cell proliferation.<ref name="Fujimaki Cancer">{{cite journal|last=Fujimaki |first=Takamitsu |author2=Masao Matsutani |author3=Osamu Nakamura |author4=Akio Asai |author5=Nobuaki Funada |author6=Morio Koike |author7=Hiromu Segawa |author8=Kouichi Aritake |author9=Takanori Fukushima |author10=Shuntaro Houjo |author11=Akira Tamura |author12=Keiji Sano |title=Correlation Between Bromodeoxyuridine- Labeling Indices and Patient Prognosis in Cerebral Astrocytic Tumors of Adults|journal=Cancer|date=29 June 2006|volume=67|issue=6|pages=1629–1634|doi=10.1002/1097-0142(19910315)67:6<1629::AID-CNCR2820670626>3.0.CO;2-E|pmid=2001552|doi-access=free }}</ref><ref name="Cytometry Myelotoxic">{{cite journal|last=Hoshino|first=Takao|author2=Tadashi Nagashima|author3=Judith Murovic|author4=Ellen M. Levin|author5=Victor A. Levin|author6=Stephen M. Rupp|title=Cell Kinetic Studies of In Situ Human Brain Tumors With Bromodeoxyuridine|journal=Cytometry|year=1985|volume=6|issue=6|pages=627–632|doi=10.1002/cyto.990060619|pmid=2998714|doi-access=free}}</ref> However, at ] concentrations, BrdU becomes myelosuppressive, thus limiting its use for radiosensitizing.<ref name="Cancer Research" /> Because BrdU can replace ] during DNA replication, it can cause ]s, and its use is therefore potentially a health hazard.{{cn|date=March 2021}} However, because it is neither ] nor ] at labeling concentrations, it is widely preferred for ''in vivo'' studies of ] cell proliferation.<ref name="Fujimaki Cancer">{{cite journal|last=Fujimaki |first=Takamitsu |author2=Masao Matsutani |author3=Osamu Nakamura |author4=Akio Asai |author5=Nobuaki Funada |author6=Morio Koike |author7=Hiromu Segawa |author8=Kouichi Aritake |author9=Takanori Fukushima |author10=Shuntaro Houjo |author11=Akira Tamura |author12=Keiji Sano |title=Correlation Between Bromodeoxyuridine- Labeling Indices and Patient Prognosis in Cerebral Astrocytic Tumors of Adults|journal=Cancer|date=1991|volume=67|issue=6|pages=1629–1634|doi=10.1002/1097-0142(19910315)67:6<1629::AID-CNCR2820670626>3.0.CO;2-E|pmid=2001552|doi-access=free }}</ref><ref name="Cytometry Myelotoxic">{{cite journal|last=Hoshino|first=Takao|author2=Tadashi Nagashima|author3=Judith Murovic|author4=Ellen M. Levin|author5=Victor A. Levin|author6=Stephen M. Rupp|title=Cell Kinetic Studies of In Situ Human Brain Tumors With Bromodeoxyuridine|journal=Cytometry|year=1985|volume=6|issue=6|pages=627–632|doi=10.1002/cyto.990060619|pmid=2998714|doi-access=free}}</ref> However, at ] concentrations, BrdU becomes myelosuppressive, thus limiting its use for radiosensitizing.<ref name="Cancer Research" />


BrdU differs from ] in that BrdU substitutes a ] atom for ] CH<sub>3</sub> group. The Br substitution can be used in X-ray diffraction experiments in crystals containing either DNA or RNA. The Br atom acts as an anomalous scatterer and its larger size will affect the crystal's X-ray diffraction enough to detect ] differences as well.<ref>{{cite journal |pages=24–34 |doi=10.1107/S0909049595013288 |title=MAD Phasing Strategies Explored with a Brominated Oligonucleotide Crystal at 1.65Å Resolution |year=1996 |last1=Peterson |first1=M. R. |last2=Harrop |first2=S. J. |last3=McSweeney |first3=S. M. |last4=Leonard |first4=G. A. |last5=Thompson |first5=A. W. |last6=Hunter |first6=W. N. |last7=Helliwell |first7=J. R. |author-link7=John R. Helliwell|journal=Journal of Synchrotron Radiation |volume=3 |pmid=16702655 |issue=Pt 1|doi-access=free |bibcode=1996JSynR...3...24P }}</ref><ref>{{cite journal |pages=374–80 |doi=10.1107/S0907444909051609 |pmc=2852301 |title=The magic triangle goes MAD: Experimental phasing with a bromine derivative |year=2010 |last1=Beck |first1=Tobias |last2=Gruene |first2=Tim |last3=Sheldrick |first3=George M. |journal=Acta Crystallographica Section D |volume=66 |issue=4 |pmid=20382990|bibcode=2010AcCrD..66..374B }}</ref> BrdU differs from ] in that BrdU substitutes a ] atom for ] CH<sub>3</sub> group. The Br substitution can be used in X-ray diffraction experiments in crystals containing either DNA or RNA. The Br atom acts as an anomalous scatterer and its larger size will affect the crystal's X-ray diffraction enough to detect ] differences as well.<ref>{{cite journal |pages=24–34 |doi=10.1107/S0909049595013288 |title=MAD Phasing Strategies Explored with a Brominated Oligonucleotide Crystal at 1.65Å Resolution |year=1996 |last1=Peterson |first1=M. R. |last2=Harrop |first2=S. J. |last3=McSweeney |first3=S. M. |last4=Leonard |first4=G. A. |last5=Thompson |first5=A. W. |last6=Hunter |first6=W. N. |last7=Helliwell |first7=J. R. |author-link7=John R. Helliwell|journal=Journal of Synchrotron Radiation |volume=3 |pmid=16702655 |issue=Pt 1|doi-access=free |bibcode=1996JSynR...3...24P }}</ref><ref>{{cite journal |pages=374–80 |doi=10.1107/S0907444909051609 |pmc=2852301 |title=The magic triangle goes MAD: Experimental phasing with a bromine derivative |year=2010 |last1=Beck |first1=Tobias |last2=Gruene |first2=Tim |last3=Sheldrick |first3=George M. |journal=Acta Crystallographica Section D |volume=66 |issue=4 |pmid=20382990|bibcode=2010AcCrD..66..374B }}</ref>

Latest revision as of 18:51, 15 June 2024

Compound commonly used to detect proliferating cells
This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (February 2021) (Learn how and when to remove this message)
Bromodeoxyuridine
Names
IUPAC name 5-Bromo-2′-deoxyuridine
Systematic IUPAC name 5-Bromo-1-pyrimidine-2,4(1H,3H)-dione
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.000.378 Edit this at Wikidata
MeSH Bromodeoxyuridine
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1Key: WOVKYSAHUYNSMH-RRKCRQDMSA-N
  • InChI=1/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1Key: WOVKYSAHUYNSMH-RRKCRQDMBM
SMILES
  • c1c(c(=O)c(=O)n12C((O2)CO)O)Br
Properties
Chemical formula C9H11BrN2O5
Molar mass 307.100 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). ☒N verify (what is  ?) Infobox references
Chemical compound

Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU, BUdR, BrdUrd, broxuridine) is a synthetic nucleoside analogue with a chemical structure similar to thymidine. BrdU is commonly used to study cell proliferation in living tissues and has been studied as a radiosensitizer and diagnostic tool in people with cancer.

During the S phase of the cell cycle (when DNA replication occurs), BrdU can be incorporated in place of thymidine in newly synthesized DNA molecules of dividing cells. Cells that have recently performed DNA replication or DNA repair can be detected with antibodies specific for BrdU using techniques such as immunohistochemistry or immunofluorescence. BrdU-labelled cells in humans can be detected up to two years after BrdU infusion.

Because BrdU can replace thymidine during DNA replication, it can cause mutations, and its use is therefore potentially a health hazard. However, because it is neither radioactive nor myelotoxic at labeling concentrations, it is widely preferred for in vivo studies of cancer cell proliferation. However, at radiosensitizing concentrations, BrdU becomes myelosuppressive, thus limiting its use for radiosensitizing.

BrdU differs from thymidine in that BrdU substitutes a bromine atom for thymidine's CH3 group. The Br substitution can be used in X-ray diffraction experiments in crystals containing either DNA or RNA. The Br atom acts as an anomalous scatterer and its larger size will affect the crystal's X-ray diffraction enough to detect isomorphous differences as well.

Bromodeoxyuridine releases gene silencing caused by DNA methylation.

BrdU can also be used to identify microorganisms that respond to specific carbon substrates in aquatic and soil environments. A carbon substrate added to the incubations of environmental samples will cause the growth of microorganisms that can utilize that substrate. These microorganisms will then incorporate BrdU into their DNA as they grow. Community DNA can then be isolated and BrdU-labeled DNA purified using an immunocapture technique. Subsequent sequencing of the labeled DNA can then be used to identify the microbial taxa that participated in the degradation of the added carbon source.

However, it is not certain whether all microbes present in an environmental sample can incorporate BrdU into their biomass during de novo DNA synthesis. Therefore, a group of microorganisms may respond to a carbon source but go undetected using this technique. Additionally, this technique is biased towards identifying microorganisms with A- and T-rich genomes.

DNA with BrdU transcribes as usual DNA, with guanine included in RNA as a complement to BrdU.

See also

References

  1. Lehner, Bernadette; Sandner, Beatrice; Marschallinger, Julia; Lehner, Christine; Furtner, Tanja; Couillard-Despres, Sebastien; Rivera, Francisco J.; Brockhoff, Gero; Bauer, Hans-Christian; Weidner, Norbert; Aigner, Ludwig (2011). "The dark side of BrdU in neural stem cell biology: Detrimental effects on cell cycle, differentiation and survival". Cell and Tissue Research. 345 (3): 313–28. doi:10.1007/s00441-011-1213-7. PMID 21837406. S2CID 756261.
  2. ^ Russo A, Gianni L, Kinsella TJ, Klecker RW, Jenkins J, Rowland J, Glatstein E, Mitchell JB, Collins J, Myers C (1984). "Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors". Cancer Res. 44 (4): 1702–5. PMID 6704976.
  3. Dolbeare, F (May 1995). "Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part I: Historical perspectives, histochemical methods and cell kinetics". The Histochemical Journal. 27 (5): 339–69. doi:10.1007/BF02389022. PMID 7657555. S2CID 21785471.
  4. Kee, N; S Sivalingam; R Boonstra; J.M Wojtowicz (March 2002). "The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis". Journal of Neuroscience Methods. 115 (1): 97–105. doi:10.1016/S0165-0270(02)00007-9. hdl:1807/357. PMID 11897369. S2CID 17572667.
  5. Konishi, Teruaki; Takeyasu, Akihiro; Natsume, Toshiyuki; Furusawa, Yoshiya; Hieda, Kotaro (2011). "Visualization of Heavy Ion Tracks by Labeling 3'-OH Termini of Induced DNA Strand Breaks". Journal of Radiation Research. 52 (4): 433–40. Bibcode:2011JRadR..52..433K. doi:10.1269/jrr.10097. PMID 21785232.
  6. Eriksson, Peter; Ekaterina Perfilieva; Thomas Björk-Eriksson; Ann-Marie Alborn; Claes Nordborg; Daniel A. Peterson; Fred H. Gage (1998). "Neurogenesis in the adult human hippocampus". Nature Medicine. 1313-1317. 4 (11): 1313–1317. doi:10.1038/3305. PMID 9809557.
  7. Fujimaki, Takamitsu; Masao Matsutani; Osamu Nakamura; Akio Asai; Nobuaki Funada; Morio Koike; Hiromu Segawa; Kouichi Aritake; Takanori Fukushima; Shuntaro Houjo; Akira Tamura; Keiji Sano (1991). "Correlation Between Bromodeoxyuridine- Labeling Indices and Patient Prognosis in Cerebral Astrocytic Tumors of Adults". Cancer. 67 (6): 1629–1634. doi:10.1002/1097-0142(19910315)67:6<1629::AID-CNCR2820670626>3.0.CO;2-E. PMID 2001552.
  8. Hoshino, Takao; Tadashi Nagashima; Judith Murovic; Ellen M. Levin; Victor A. Levin; Stephen M. Rupp (1985). "Cell Kinetic Studies of In Situ Human Brain Tumors With Bromodeoxyuridine". Cytometry. 6 (6): 627–632. doi:10.1002/cyto.990060619. PMID 2998714.
  9. Peterson, M. R.; Harrop, S. J.; McSweeney, S. M.; Leonard, G. A.; Thompson, A. W.; Hunter, W. N.; Helliwell, J. R. (1996). "MAD Phasing Strategies Explored with a Brominated Oligonucleotide Crystal at 1.65Å Resolution". Journal of Synchrotron Radiation. 3 (Pt 1): 24–34. Bibcode:1996JSynR...3...24P. doi:10.1107/S0909049595013288. PMID 16702655.
  10. Beck, Tobias; Gruene, Tim; Sheldrick, George M. (2010). "The magic triangle goes MAD: Experimental phasing with a bromine derivative". Acta Crystallographica Section D. 66 (4): 374–80. Bibcode:2010AcCrD..66..374B. doi:10.1107/S0907444909051609. PMC 2852301. PMID 20382990.
  11. Weiss RA (2013). "On the concept and elucidation of endogenous retroviruses". Philos. Trans. R. Soc. Lond. B Biol. Sci. 368 (1626): 20120494. doi:10.1098/rstb.2012.0494. PMC 3758183. PMID 23938748.
  12. Tada, Yuya; Grossart, Hans-Peter (2013). "Community shifts of actively growing lake bacteria after N-acetyl-glucosamine addition: improving the BrdU-FACS method". The ISME Journal. 8 (2): 441–454. doi:10.1038/ismej.2013.148. ISSN 1751-7362. PMC 3906810. PMID 23985742.
  13. Borneman J (1999). "Culture-independent identification of microorganisms that respond to specified stimuli". Appl. Environ. Microbiol. 65 (8): 3398–400. Bibcode:1999ApEnM..65.3398B. doi:10.1128/AEM.65.8.3398-3400.1999. PMC 91510. PMID 10427025.
  14. Urbach, Ena; Kevin L. Vergin; Stephen J. Giovannoni (March 1999). "Immunochemical Detection and Isolation of DNA from Metabolically Active Bacteria". Applied and Environmental Microbiology. 65 (3): 1207–1213. Bibcode:1999ApEnM..65.1207U. doi:10.1128/AEM.65.3.1207-1213.1999. PMC 91166. PMID 10049885.
  15. Hill BT, Baserga R (1975). "Effect of 5-bromodeoxyuridine on the transcriptional properties of the genome in WI-38 human diploid fibroblasts". Chem. Biol. Interact. 10 (5): 363–375. Bibcode:1975CBI....10..363H. doi:10.1016/0009-2797(75)90058-7. PMID 1095238.

External links

Categories: